Management guidelines for stage III non-small cell lung cancer

Management of stage III nonsmall cell lung cancer (NSCLC) is very challenging due to being a group of widely heterogeneous diseases that require multidisciplinary approaches with timely and coordinated care. The standards of care had significant changes over the last couple of years because of the introduction of consolidation therapy with checkpoint inhibitor following concurrent chemo-radiotherapy and the evolving new role of tyrosine kinase inhibitors in the adjuvant setting. The manuscript presents evidence-based recommendations for the workup, staging, treatment and follow up of the various subtypes of stage III NSCLC. The guidelines were developed by experts in various fields of thoracic oncology and guidelines development. The guidelines consider the sequence of interventions and the role of each discipline in the management of the disease taking into account the recent development and included required resources to help physicians provide better care.

Automated summary

Management of stage III nonsmall cell lung cancer (NSCLC) is challenging due to its heterogeneity, requiring multidisciplinary approaches. Recent changes in standards of care include consolidation therapy with checkpoint inhibitors and the evolving role of tyrosine kinase inhibitors. Evidence-based recommendations consider interventions sequence, each discipline's role, and required resources for better care.